With LeMaitre now taking care of CardioCel etc. and I'd imagine have a good relationship with Admedus, could it be possible that they could be interested in a partnership with Admedus on the new Aortic valve?
I haven't a clue as to the cost to get the valve through to FDA approval.
Is the cost too much for them to take on?
For a company that wants to grow in this area, it would be a fantastic attachment to have, a company maker
Admedus has got a proven product in ADAPT. that has a number of other possible products already mentioned by the company that definitely requiring further research.
Or am I barking up the wrong tree?
Interested in other peoples thought, thanks.
Regards
Dabru
Admedus in Good shape, interview with CEO Wayne Paterson, page-10
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
-0.500(3.19%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.75 | $15.75 | $15.00 | $294.3K | 19.33K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1135 | $15.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.35 | 88 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |